<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770185</url>
  </required_header>
  <id_info>
    <org_study_id>I192</org_study_id>
    <secondary_id>CAN-NCIC-IND192</secondary_id>
    <secondary_id>ARIAD-CAN-NCIC-IND192</secondary_id>
    <secondary_id>CDR0000614597</secondary_id>
    <nct_id>NCT00770185</nct_id>
  </id_info>
  <brief_title>Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer</brief_title>
  <official_title>A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Ridaforolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of ridaforolimus and to see how&#xD;
      well it works in treating patients with recurrent metastatic and/or locally advanced&#xD;
      endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess the efficacy, in terms of objective response rate, of ridaforolimus, in&#xD;
           patients with recurrent metastatic and/or locally advanced endometrial cancer.&#xD;
&#xD;
        -  To assess the adverse events, time to progression, and response duration of this drug in&#xD;
           these patients.&#xD;
&#xD;
        -  To correlate objective tumor response with PTEN expression and other potential markers&#xD;
           in primary tumor tissue from these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral ridaforolimus once daily on days 1-5 for 4 weeks. Courses repeat every&#xD;
      4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Archived tumor tissue samples (paraffin block or unstained slides) are analyzed for PTEN gene&#xD;
      expression and other mTOR pathway elements to explore possible markers of response or&#xD;
      non-progression by immunohistochemistry.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3 months&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2008</start_date>
  <completion_date type="Actual">February 13, 2015</completion_date>
  <primary_completion_date type="Actual">March 19, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response measured by RECIST criteria</measure>
    <time_frame>every 8 weeks</time_frame>
    <description>After every second cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 years</time_frame>
    <description>Adverse events will be monitored and assessed from the time of the first dose with overall results being assessed at final analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between objective tumor response with PTEN expression and other potential markers</measure>
    <time_frame>4 years</time_frame>
    <description>will be assessed overall at the time of completion of therapy and final analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>4 years</time_frame>
    <description>After progression with overall results assessed at final analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Ridaforolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ridaforolimus</intervention_name>
    <description>oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)</description>
    <arm_group_label>Ridaforolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Ridaforolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Ridaforolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Ridaforolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed endometrial cancer, including any 1 of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
                    -  Papillary serous&#xD;
&#xD;
                    -  Papillary&#xD;
&#xD;
                    -  Villoglandular&#xD;
&#xD;
                    -  Mucinous&#xD;
&#xD;
                    -  Clear cell&#xD;
&#xD;
               -  Endometrioid&#xD;
&#xD;
               -  Adenosquamous carcinoma&#xD;
&#xD;
          -  Recurrent or metastatic and/or locally advanced disease&#xD;
&#xD;
          -  Incurable disease by standard therapies&#xD;
&#xD;
          -  Clinically and/or radiologically documented disease within the past 28 days (35 days&#xD;
             if negative), defined as ≥ 1 unidimensionally measurable disease site meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  At least 20 mm by x-ray or physical exam&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  At least 20 mm by non-spiral CT scan&#xD;
&#xD;
          -  Available tumor tissue (paraffin block or unstained slides) from primary tumor&#xD;
&#xD;
          -  No uterine sarcoma (leiomyosarcoma), mixed müllerian tumor (MMT), and/or adenosarcoma&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Clinical suspicion of CNS involvement requires a head CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.25 times ULN OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Fasting serum cholesterol ≤ 9.0 mmol/L&#xD;
&#xD;
          -  Fasting triglycerides ≤ 4.56 mmol/L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Accessible for treatment and follow up (e.g., 1 ½ hours driving distance from&#xD;
             participating center)&#xD;
&#xD;
          -  No upper gastrointestinal or other condition that would impair swallowing or&#xD;
             absorption of oral medication&#xD;
&#xD;
          -  No serious illness or medical condition that would not permit the patient to be&#xD;
             managed according to the protocol, including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorder (e.g., uncontrolled&#xD;
                  psychotic disorders) that would impair the ability to obtain consent or limit&#xD;
                  compliance with study requirements&#xD;
&#xD;
               -  Active uncontrolled or serious infection&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months, congestive heart failure (even if&#xD;
                  medically controlled), unstable angina, active cardiomyopathy, unstable&#xD;
                  ventricular arrhythmia, or uncontrolled hypertension&#xD;
&#xD;
               -  Pulmonary disease requiring oxygen&#xD;
&#xD;
               -  HIV infection or other immune deficiency&#xD;
&#xD;
               -  Other medical conditions that might be aggravated by study treatment&#xD;
&#xD;
          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer,&#xD;
             curatively treated carcinoma in situ of the cervix, or other solid tumors curatively&#xD;
             treated with no evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  No known hypersensitivity to the study drug or its components&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 7 days since prior hormonal therapy (progestational or aromatase inhibitor)&#xD;
             as either adjuvant therapy or for treatment of metastatic disease&#xD;
&#xD;
          -  At least 21 days since prior major surgery and recovered&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy and recovered&#xD;
&#xD;
               -  Prior low-dose palliative radiotherapy allowed&#xD;
&#xD;
          -  At least 4 months since prior adjuvant chemotherapy&#xD;
&#xD;
          -  No prior mTOR inhibitors&#xD;
&#xD;
          -  No prior or concurrent chemotherapy for metastatic or recurrent disease&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent CYP3A4 inhibitors including, but not&#xD;
             limited to, any of the following:&#xD;
&#xD;
               -  Azole antifungals (i.e., ketoconazole, itraconazole, miconazole, fluconazole)&#xD;
&#xD;
               -  HIV protease inhibitors (i.e., indinavir, saquinavir, ritonavir, atazanavir,&#xD;
                  nelfinavir)&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Telithromycin&#xD;
&#xD;
          -  More than 12 days since prior and no concurrent CYP3A4 inducers including, but not&#xD;
             limited to, any of the following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  St. John's wort&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent investigational drugs or anticancer&#xD;
             therapy (e.g., immunotherapy, biological response modifiers [excluding hematopoietic&#xD;
             growth factors], and systemic hormonal therapy)&#xD;
&#xD;
          -  No concurrent CYP3A4 substrates&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit M. Oza, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014 Nov;135(2):184-9. doi: 10.1016/j.ygyno.2014.06.033. Epub 2014 Aug 28.</citation>
    <PMID>25173583</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>endometrial adenosquamous cell carcinoma</keyword>
  <keyword>endometrial clear cell carcinoma</keyword>
  <keyword>endometrial papillary carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

